Beijing, China, July 11, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced its independently developed key technology of RenMabTM platform has been granted a Chinese patent. The patent is related to the key technology of Biocytogen’s fully human antibody RenMab platform and the company has recently received the patent certificate issued by the China National Intellectual Property Administration. The RenMab technology platform is used to directly obtain fully human antibodies from immunized mice, which greatly improves the efficiency of developing fully human antibody drugs. The issued patent further solidifies Biocytogen’s competitiveness in the field of antibody drug development. In addition to China, the company has submitted patent applications for the RenMab platform in the United States, Europe, Japan, Singapore, Russia, Israel, Australia, and other countries and regions. The applications in these countries are in progress.
Using Biocytogen’s independently developed Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the company replaced the genes encoding the whole variable regions of both heavy and light chains of mouse antibodies with human counterparts in situ to generate a fully human antibody mouse (RenMab) that possesses the complete human antibody heavy chain VDJ and light chain VJ genes. The RenMab platform, independently developed by Biocytogen, is one of the leading mouse platforms in the world that has the complete human antibody variable region gene replacement. RenMab mice can generate fully human monoclonal antibodies that exhibit low immunogenicity, high diversity, specificity, affinity and excellent physiochemical properties.
In addition to the RenMab platform, Biocytogen’s independently developed fully human antibody RenMiceTM platforms also include RenLite® and RenNano® mouse platforms, as well as platforms with additional modifications. These comprehensive platforms enable the development of drugs with various modalities, including fully human monoclonal antibodies, bispecific antibodies, antibody-drug-conjugates (ADCs), and fully human nanobodies, which can support the diverse research and development needs of pharmaceutical companies worldwide.
Since its release in 2019, RenMice platforms have gained worldwide recognition in the biotech and biopharmaceutical industry. Biocytogen has reached RenMice licensing agreements with dozens of companies, including Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences and Remegen.
Harnessing the RenMice platforms, Biocytogen launched Project Integrum, which aims to identify antibody-based drugs for more than 1000 targets. It is anticipated that this project will result in a library containing hundreds of thousands of fully human antibody sequences, to meet pharmaceutical companies’ demands for novel drug development. As of June 30, 2023, 50 therapeutic antibody development/out-licensing/transfer agreements have been established worldwide and these agreements encompass various drug modalities, including monoclonal antibodies, bispecific and multi-specific antibodies, ADCs, cell therapy, etc.
This Chinese patent authorization of the RenMab technology platform demonstrates Biocytogen’s outstanding innovation ability and robust intellectual property protection system. It is also an important guarantee for the company to continue supporting worldwide partners with intellectual property rights protected. In the future, Biocytogen will continue to engage in global patent strategies and protect key technologies, and looks forward to obtaining more patent authorizations for the subsequent RenLite, RenNano, and other proprietary fully human antibody mouse platforms.
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMiceTM licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.